Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial

Abstract Background Both enzalutamide and abiraterone have demonstrated improved radiographic progression-free and overall survival for castration-resistant prostate cancer (CRPC) compared with placebo controls before docetaxel treatment in phase III studies. These oral agents target androgen and an...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Kouji Izumi, Atsushi Mizokami, Mikio Namiki, Shogo Inoue, Nobumichi Tanaka, Yuko Yoshio, Kei Ishibashi, Manabu Kamiyama, Noriyasu Kawai, Hideki Enokida, Takashi Shima, Shizuko Takahara
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2017-10-01
coleção:	BMC Cancer
Assuntos:	Androgen-deprivation therapy Hormone therapy Endocrine therapy Castration-resistant prostate cancer Enzalutamide Abiraterone
Acesso em linha:	http://link.springer.com/article/10.1186/s12885-017-3661-2
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!